STimulation to Activate RespIration
NCT: NCT06832306 · RECRUITING
Brief Summary
Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute respiratory distress syndrome (ARDS)) will be randomized 2:1 to diaphragm neurostimulation-assisted ventilation (DNAV) using the AeroNova System plus lung-protective ventilation (Treatment) vs. lung-protective ventilation alone (Control).
Frequently Asked Questions
What is STimulation to Activate RespIration?
STimulation to Activate RespIration is a clinical trial registered under NCT06832306. Current status: RECRUITING.
What is the status of NCT06832306?
The current status of NCT06832306 (STimulation to Activate RespIration) is: RECRUITING.
When did STimulation to Activate RespIration start?
STimulation to Activate RespIration started on 2025-05-28.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.